This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNST Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Constellation Pharmaceuticals Stock (NASDAQ:CNST) 30 days 90 days 365 days Advanced Chart Get CNST alerts:Sign Up Key Stats Today's Range$33.99▼$33.9950-Day Range$33.63▼$33.9952-Week Range$17.00▼$39.30VolumeN/AAverage Volume940,325 shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More… Receive CNST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNST Stock News HeadlinesConstellation Brands Slashes Outlook on Weakening Wine Business. Why the Stock Is Up.September 4, 2024 | msn.comPlc Gsk's Net WorthAugust 18, 2024 | benzinga.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 22, 2025 | Crypto Swap Profits (Ad)China will launch first satellites of constellation to rival Starlink, newspaper reportsAugust 6, 2024 | msn.comConstellation Energy forecasts annual profit above estimatesAugust 6, 2024 | reuters.comVHCP Management II, LLC's Net WorthMay 22, 2024 | benzinga.comYour guide to Constellation Field, home of the Sugar Land Space CowboysApril 20, 2023 | chron.comConstellation SoftwareMarch 8, 2023 | forbes.comSee More Headlines CNST Stock Analysis - Frequently Asked Questions How were Constellation Pharmaceuticals' earnings last quarter? Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) posted its quarterly earnings results on Sunday, May, 9th. The company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $0.05. When did Constellation Pharmaceuticals IPO? Constellation Pharmaceuticals (CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. What other stocks do shareholders of Constellation Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Kinross Gold (KGC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Gilead Sciences (GILD) and OPKO Health (OPK). Company Calendar Last Earnings5/09/2021Today6/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CNST CIK29806 Webwww.constellationpharma.com Phone617-714-0555FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$126.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-33.12% Return on Assets-29.92% Debt Debt-to-Equity RatioN/A Current Ratio15.39 Quick Ratio15.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.63 per share Price / Book3.94Miscellaneous Outstanding Shares47,915,000Free FloatN/AMarket Cap$1.63 billion OptionableNot Optionable Beta2.59 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CNST) was last updated on 6/22/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Constellation Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Constellation Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.